Validation of the MiCK Assay
Conditions
Mesothelioma, Small Cell Lung Cancer, NSCLC
Conditions: official terms
Mesothelioma - Small Cell Lung Carcinoma
Study Type
Observational [Patient Registry]
Study Phase
N/A
Study Design
Observational Model: Cohort, Time Perspective: Prospective
Overall Status
Recruiting
Summary
Testing Mayo Clinic cancer patients with the results being correlated with prior patient therapy, performance status, and extent of disease.
Detailed Description
This study will be conducted in two phases.

During the Feasibility Phase, specimens from any tumor will be sent to the central DiaTech MiCK assay laboratory to determine the ease of sample acquisition, processing, transport, and assay interpretation.

Once DiaTech has completed analyses for the feasibility phase specimens and has confirmed that the sample acquisition, processing, transport, and assay interpretation are appropriate, we will proceed with the Demonstration Phase.

During the Mesothelioma Demonstration Phase, 20 mesothelioma samples will be assayed and the results will be correlated with prior patient therapy, performance status, and extent of disease.
Criteria for eligibility
Healthy Volunteers: Accepts Healthy Volunteers
Maximum Age: N/A
Minimum Age: 18 Years
Gender: Both
Criteria: Inclusion Criteria:

- 20 subjects diagnosed with mesothelioma and 10 diagnosed with any malignancy.

Exclusion Criteria:

- patients that a sample cannot obtained for testing.
Location
Mayo Validation Support Services 3050 Superior Drive NW
Rochester, Minnesota, United States
Status: Recruiting
Contact: Mary Karaus - 507-538-8472 - karaus.mary@mayo.edu
Start Date
June 2012
Completion Date
March 2015
Sponsors
DiaTech Oncology
Source
DiaTech Oncology
Record processing date
ClinicalTrials.gov processed this data on July 28, 2015
ClinicalTrials.gov page